Implantação do modelo experimental da síndrome da asma e rinite alérgicas combinadas no laboratório de imunofarmacologia da Universidade Federal da Paraíba.

Abstract

The Combined Allergic Rhinitis and Asthma Syndrome (CARAS) is characterized by being a unique disease of the airways, due to the intimate connection in the genesis of both diseases. Asthma and rhinitis share the same etiologic agents, inflammatory processes and therapeutic principles. The present study aimed to implant the experimental model of CARAS induced by ovalbumin (OVA), in the Laboratory of Immunopharmacology (LIMFA) / UFPB. Female BALB / c mice were used in the OVA sensitization process and, on days zero and seven, the animals were sensitized intraperitoneally with OVA-V (10μg / 2.0mg aluminum hydroxide) and OVA-V challenge (5mg / mL) by nasal instillation for three consecutive days in three consecutive weeks. From day 38, the animals were challenged with aerosol of OVAII (5% / 30 minutes) for five consecutive days. On the 43rd day, the outcome of the experimental protocol was obtained with the collection of biological material such as: nasal lavage (NALF), bronchoalveolar lavage (BALF), head, lung and blood for the appropriate analysis. The challenge with OVA in the sensitized animals promoted a significant increase (p <0.001) in the clinical signs of rhinitis: nasal rubbing and sneezing in the weeks evaluated (1st, 2nd, 3rd and 4th) after OVA challenges when compared with the basal group. Similar results occurred in the nasal friction and sneezing after histamine-induced nasal reactivity (0.1, 1.0, 10, 100, 1000 nmol). The NALF and BALF analyzes demonstrated that the OVA challenges induced significant increases (p <0.001) in the number of total inflammatory cells (105) when compared with the Basal group. In the NALF there was a percentage increase (p <0.001) of eosinophils. However, in BALF there was an increase in the number of cells (p <0.001) such as: eosinophils, macrophages and lymphocytes. In the analysis of the histological sections of the nasal cavity in the OVA group compared to the basal, there was an increase (p <0.001) in the cellular migration, and in the lung tissue there was an increase (p <0.001) in cell migration, mucus hyper production and tissue remodeling demonstrating tissue inflammation. The OVA group presented a significant increase (p <0.001) in total IgE and OVA-specific IgE; in cytokines (IL4 and IL-13) and decreased in IFNγ / IL-4 ratio when compared to the Basal group. However, IFNγ concentrations were significantly decreased (p <0.01) in the OVA group it was observed no changes in IL-10 concentration. Activation of p65 NF-κB was evidenced in the OVA group in detriment to the Basal group. In view of the above, we concluded the effective implantation of the experimental protocol of CARAS induced by OVA in the Laboratory of Immunopharmacology / UFPB, and thus can be used to test new molecules in the treatment of this syndrome.